Identification of SLC7A1 as a potential therapeutic target for high-grade meningioma

High-grade meningioma remains a therapeutic challenge to medical oncologists. It is urgent to uncover novel molecular targets. Solute carrier family 7 member 1 (SLC7A1) was highly expressed in high-grade meningioma and associated with poor prognosis of patients. SLC7A1 knockdown significantly inhibited the proliferation and invasion of malignant meningioma cells. In addition, the small-molecule drug AZ628 showed an excellent antiproliferative effect on malignant meningioma cells, indicating that it is a potential antitumor drug for high-grade meningioma. Our study revealed the essential roles of SLC7A1 in the malignant progression of meningioma, suggesting SLC7A1 as a potential antitumor target for high-grade meningioma. In order to verify the molecular function of SLC7A1 in meningioma cells, we knocked down the expression of SLC7A1 in two meningioma cell lines and performed RNA sequencing. Additionally, to explore the anti-tumor mechanism of AZ628, we treated two meningioma cell lines with AZ628 and conducted RNA sequencing.